iBio Announces Collaboration User Manual

December 23, 2019

iBio Announces Collaboration with
EdgePoint AI for Next Gen Quality in
Biologics Manufacturing

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO)
today announced that it has entered into a collaboration with EdgePoint AI, a division of
Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial
intelligence (“AI”)/blockchain-driven vision system for pharmaceutical manufacturing, known
as TrustPoint Fabric. Initial implementation will occur at iBio’s state-of-the-art production
facility for the optimization of raw material documentation and verification activities.

Using blockchain technology, TrustPoint Fabric enables automated data generation and
capture to remain immutable and fully auditable. Thus, when fully implemented, iBio aims to
deliver the highest-level of compliance to the pharmaceutical industry’s standards for data
integrity. Concurrently, the enhanced automation capabilities are expected to lower
operating costs while improving quality for clients of iBio’s biologics contract development
and manufacturing services.

“We are proud to take part in efforts to bring emerging technologies like TrustPoint Fabric
into the pharmaceutical manufacturing realm,” stated Robert Erwin, President of iBio.
“Adding this technology to our automated biologics manufacturing facility is a natural fit and
may yield substantial benefits. The potential to reduce costs by streamlining labor intensive
manual operations while improving quality is very attractive as we continue to grow our
position as the leading plant-based biologics CDMO.”

“We are excited that a leading plant-based CDMO like iBio has chosen to pilot TrustPoint
Fabric,” commented Vuong Trieu, Ph.D., CEO of Mateon Therapeutics. “The platform has
broad application potential across virtually all types of pharmaceutical manufacturing
including biologics, cell and gene therapy, small molecule manufacturing, bulk drug
substance, fill finish, packaging and labeling. Accordingly, and assuming everything goes as
planned, we envision the application of TrustPoint Fabric in iBio’s cGMP manufacturing raw
material supply chain will be the first in a series of implementations, both with iBio as well as
other potential EdgePoint customers.”

About iBio

iBio, Inc., is a global leader in plant-based biologics manufacturing.
Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver gram quantities of high-quality monoclonal
antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO
LLC, provides FastPharming Contract Development and Manufacturing Services via its
130,000 square foot facility in Bryan, Texas. iBio CDMO also enables innovators to use

the FastPharming System for insourced manufacturing via its Factory Solutions “design­and-build” services. iBio’s FastGlycaneering Development Service™ includes an array of
new glycosylation technologies for engineering high-performance recombinant proteins.
Additionally, iBio is developing its own proprietary products which include its lead asset,
IBIO-100, for the treatment of fibrotic diseases. For more information, visit www.ibioinc.com.

About EdgePoint AI

EdgePoint AI was established in order to advance the company’s revolutionary cluster­computer platform for AI that crunches machine learning models at a fraction of the power
and budget of mainstream computing in pharmaceutical manufacturing. The company’s
technology platform, called TrustPoint Fabric, provides for an AI computing platform for
pharmaceutical and healthcare verticals, including blockchain support for manufacturing
where data integrity and security are of utmost importance. EdgePoint’s management team
is composed of executives with deep pharmaceutical drug development, GMP
manufacturing and AI knowledge.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY
CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS
INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE
FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE
COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE
NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF
PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD
AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S
REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen Kilmer
Investor Relations
[phone]

[e-mail]

Source: iBio, Inc.